IGM Financial Inc. (TSX: IGM) ("IGM") announced today that it has completed its previously announced offering of $200 million principal amount of 4.407% debentures due June 2, 2036 and $200 million ...

MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of 1,597,827 ...

IGM Financial (IGIFF) has priced a private placement issuance of $400 million in aggregate principal amount of debentures, offered on a best-efforts basis through an agent syndicate co-led by BMO ...

IGM Financial Inc. (IGM) (TSX: IGM) today reported record high total assets under management and advisement of $325.8 billion at April 30, 2026, up 20.9% from $269.5 billion at April 30, 2025. Total ...

On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies ...

Various biological cascades respond to alerting signals against life-threatening events, such as tissue injury. In most cases, the production of effector molecules is rapidly upregulated via an ...